TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 17650171

Group type: COMPARATOR
Intervention: Rinsing with water
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Soaking in an alkaline peroxide solution (Bonyplus)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Brushing with dentifrice (Dentu‐Creme) and soft Johnson and Johnson's toothbrush
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Combination of soaking and brushing (methods 2 and 3)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Brushing with dentifrice (Dentu‐Creme) and soft Oral B toothbrush
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Combination of soaking and brushing (methods 2 and 5)
Number of subjects: 36
Study: 16301884

Group type: EXPERIMENTAL
Intervention: Propofol (1 mg/kg IV) + remifentanil (1 microg/kg)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Propofol (1 mg/kg IV)
Number of subjects: 21
Study: 11896441

Group type: EXPERIMENTAL
Intervention: dl1520 gene therapy
Number of subjects: 10

Group type: COMPARATOR
Intervention: Percutaneous ethanol injection (control group)
Number of subjects: 10
Study: 9790607

Group type: EXPERIMENTAL
Intervention: Assessment-driven algorithm for treatment of pediatric status asthmaticus
Number of subjects: 201

Group type: COMPARATOR
Intervention: Unstructured standard treatment
Number of subjects: 201
Study: 7631682

Group type: EXPERIMENTAL
Intervention: Indomethacin
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Sulindac
Number of subjects: 20
Study: 2533582

Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg s.I.)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 342627

Group type: EXPERIMENTAL
Intervention: Inactivated influenza virus vaccine (200 CCA units of influenza A/New Jersey/76 and 200 CCA units of influenza A/Victoria/75)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88

Group type: COMPARATOR
Intervention: Untreated control
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Inactivated influenza virus vaccine
Number of subjects: 88
Study: 31096775

Group type: EXPERIMENTAL
Intervention: 10 mg vericiguat
Number of subjects: 735

Group type: EXPERIMENTAL
Intervention: 15 mg vericiguat
Number of subjects: 735

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 735
Study: 27933425

Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 211

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 211
Study: 27120065

Group type: EXPERIMENTAL
Intervention: Acetylspiramycin plus garlicin
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Acetylspiramycin only
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Garlicin only
Number of subjects: 151

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 151
Study: 23616126

Group type: EXPERIMENTAL
Intervention: EUS - CGN
Number of subjects: 68

Group type: COMPARATOR
Intervention: EUS - CPN
Number of subjects: 68
Study: 22121861

Group type: EXPERIMENTAL
Intervention: Continuation of antipsychotic treatment for at least 6 months
Number of subjects: 20

Group type: COMPARATOR
Intervention: Gradual withdrawal of antipsychotic treatment
Number of subjects: 20
Study: 19967647

Group type: EXPERIMENTAL
Intervention: Sevelamer
Number of subjects: 360

Group type: COMPARATOR
Intervention: Calcium-binder phosphate
Number of subjects: 360
Study: 17182194

Group type: EXPERIMENTAL
Intervention: Drinker Inventory of Consequences (DrInC)
Number of subjects: 1382

Group type: EXPERIMENTAL
Intervention: 15-item Short Inventory of Problems (SIP)
Number of subjects: 1382
Study: 15094539

Group type: EXPERIMENTAL
Intervention: Lumbar fusion
Number of subjects: 284

Group type: COMPARATOR
Intervention: Nonsurgical treatment
Number of subjects: 284
Study: 12473554

Group type: EXPERIMENTAL
Intervention: Antioxidant vitamin C (25 mg/min; IA)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Endothelium‐bound ecSOD activity
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Endothelium‐bound xanthine‐oxidase activity
Number of subjects: 14

Group type: COMPARATOR
Intervention: Vitamin C
Number of subjects: 14
Study: 9809262

Group type: EXPERIMENTAL
Intervention: Caregiver-based intervention program (12-week intervention with lectures and on-site consultations)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Day care alone
Number of subjects: 35
Study: 7707809

Group type: EXPERIMENTAL
Intervention: 200 micrograms TRH intravenously every 12 h up to a maximum of four doses
Number of subjects: 1234

Group type: COMPARATOR
Intervention: Placebo intravenously every 12 h up to a maximum of four doses
Number of subjects: 1234
Study: 2269171

Group type: EXPERIMENTAL
Intervention: HA granules with ePTFE membrane
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: ePTFE membrane alone
Number of subjects: 4

Group type: COMPARATOR
Intervention: HA granules alone (Control)
Number of subjects: 4
Study: 628535

Group type: EXPERIMENTAL
Intervention: Ypsilon‐Y intrauterine device (IUD)
Number of subjects: 347

Group type: COMPARATOR
Intervention: Lippes loop D
Number of subjects: 347
Study: 30945510

Group type: EXPERIMENTAL
Intervention: Magnesium alginate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Proton pump inhibitors (PPI)
Number of subjects: 0
Study: 29957285

Group type: EXPERIMENTAL
Intervention: Selective upper airway stimulation (sUAS)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control group (patients younger than 65 years with matched AHI and BMI)
Number of subjects: 62
Study: 26574625

Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg/day for 8 weeks
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (non-treated SLE patients)
Number of subjects: 64
Study: 23873857

Group type: EXPERIMENTAL
Intervention: Complete percutaneous approach (pre-closure technique)
Number of subjects: 274

Group type: COMPARATOR
Intervention: Surgical cut-down/repair
Number of subjects: 274
Study: 22006502

Group type: EXPERIMENTAL
Intervention: Topical silver sulfadiazine (SSD) cream 1%, three times a day, 3 days a week, for 5 weeks during radiotherapy and one week thereafter
Number of subjects: 102

Group type: COMPARATOR
Intervention: General skin care (Control)
Number of subjects: 102
Study: 19013762

Group type: EXPERIMENTAL
Intervention: Active microbicide
Number of subjects: 132

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: ACASI
Number of subjects: 132
Study: 17203297

Group type: EXPERIMENTAL
Intervention: Radon (plus CO2) baths
Number of subjects: 134

Group type: COMPARATOR
Intervention: Artificial CO2 baths
Number of subjects: 134
Study: 15465502

Group type: EXPERIMENTAL
Intervention: Hormone replacement therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Etidronate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Calcitonin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Alfacalcidol
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Vitamin K
Number of subjects: 0
Study: 11400999

Group type: EXPERIMENTAL
Intervention: Tryptophan depletion (TD)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control session (no TD)
Number of subjects: 10
Study: 9389807

Group type: EXPERIMENTAL
Intervention: 200 mg/d P vaginally
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 400 mg/d P vaginally
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: 100 mg/d P vaginally
Number of subjects: 20
Study: 7898010

Group type: EXPERIMENTAL
Intervention: T-activin
Number of subjects: 105
Study: 3229874

Group type: EXPERIMENTAL
Intervention: Acetyl-L-carnitine, 2 g/day for three months
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 29334645

Group type: EXPERIMENTAL
Intervention: Full-threshold depressive disorder (n = 24)
Number of subjects: 82

Group type: COMPARATOR
Intervention: No full-threshold depressive disorder
Number of subjects: 82
Study: 27007753

Group type: EXPERIMENTAL
Intervention: Quantitative Light‐induced Fluorescence‐Digital (QLF) images
Number of subjects: 33

Group type: COMPARATOR
Intervention: White light (WL)
Number of subjects: 33
Study: 24297579

Group type: EXPERIMENTAL
Intervention: Antiplatelets 24 hours after recombinant tissue plasminogen activator (group A)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Antiplatelets for patients without SWI-visualised haemorrhage (group B)
Number of subjects: 146

Group type: COMPARATOR
Intervention: Comparison between groups A and B
Number of subjects: 146
Study: 23448854

Group type: EXPERIMENTAL
Intervention: Video Laryngoscopy (VL)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Direct Laryngoscopy (DL)
Number of subjects: 69

Group type: COMPARATOR
Intervention: Pediatric residents (PED)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: Emergency medicine residents (EM)
Number of subjects: 69
Study: 21122200

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 157

Group type: EXPERIMENTAL
Intervention: Simvastatin and Aspirin
Number of subjects: 157
Study: 18055141

Group type: EXPERIMENTAL
Intervention: Methacholine dry powder inhaler (12.5 to 200 microg per metered dose)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Methacholine solution
Number of subjects: 18
Study: 15781524

Group type: COMPARATOR
Intervention: 5 mg single-dose extended-release epidural morphine (EREM)
Number of subjects: 541

Group type: EXPERIMENTAL
Intervention: 10 mg single-dose EREM
Number of subjects: 541

Group type: EXPERIMENTAL
Intervention: 20 mg single-dose EREM
Number of subjects: 541

Group type: EXPERIMENTAL
Intervention: 25 mg single-dose EREM
Number of subjects: 541

Group type: COMPARATOR
Intervention: 5 mg standard epidural morphine sulfate (MS)
Number of subjects: 541

Group type: EXPERIMENTAL
Intervention: Single-dose EREM (all doses)
Number of subjects: 541

Group type: EXPERIMENTAL
Intervention: Single-dose EREM (15, 20, and 25 mg)
Number of subjects: 541
Study: 12841924

Group type: EXPERIMENTAL
Intervention: Azelastine (AZE)
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Sodium cromoglycate (SCG)
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 144
Study: 10900559

Group type: EXPERIMENTAL
Intervention: Fluvoxamine (SSRI)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Behavior therapy
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 8644802

Group type: EXPERIMENTAL
Intervention: Surgery (pars plana vitrectomy with C3F8 injection and face-down positioning for two weeks)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Observation alone
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 36

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 36
Study: 1440484

Group type: EXPERIMENTAL
Intervention: Low dose heparin plus dihydroergotamine (DHE; 0.5 mg, given 8 hourly by sc injection)
Number of subjects: 117

Group type: COMPARATOR
Intervention: Low dose heparin alone (5,000 IU sodium heparin given subcutaneously [sc] 8 hourly until the seventh postoperative day)
Number of subjects: 117
Study: 3553478

Group type: EXPERIMENTAL
Intervention: Sodium-reduction intervention
Number of subjects: 131

Group type: COMPARATOR
Intervention: No-diet intervention (Control)
Number of subjects: 131
Study: 28419624

Group type: EXPERIMENTAL
Intervention: Midodrine 10 mg
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Duloxetine 80 mg
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Reboxetine 12 mg
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 27400948

Group type: EXPERIMENTAL
Intervention: Irinotecan 60 mg/m² on days 1, 8, and 15 plus cisplatin 60 mg/m² on day 1 (CPT-P group) every 4 weeks for six cycles
Number of subjects: 667

Group type: COMPARATOR
Intervention: Paclitaxel 175 mg/m² plus carboplatin AUC 6.0 mg/mL/min on day 1 (TC group) every 3 weeks for six cycles
Number of subjects: 667

Group type: EXPERIMENTAL
Intervention: Irinotecan plus cisplatin (CPT-P group)
Number of subjects: 667

Group type: COMPARATOR
Intervention: Paclitaxel plus carboplatin (TC group)
Number of subjects: 667
Study: 25929209

Group type: EXPERIMENTAL
Intervention: Covered implant set
Number of subjects: 0

Group type: COMPARATOR
Intervention: Uncovered implant set
Number of subjects: 0
Study: 24124358

Group type: EXPERIMENTAL
Intervention: salmeterol/fluticasone propionate (SFC) 50/250 μg twice daily
Number of subjects: 400

Group type: COMPARATOR
Intervention: tiotropium bromide 18 μg once daily
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: TRIPLE therapy (SFC twice daily and tiotropium once daily)
Number of subjects: 400
Study: 20377577

Group type: EXPERIMENTAL
Intervention: Dual antiretroviral therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single drug regimen
Number of subjects: 0
Study: 18333706

Group type: EXPERIMENTAL
Intervention: Telephone Care Coordination Program (including simple 2‐click referral, proactive care coordination, medication management, and 5 follow‐up telephone calls)
Number of subjects: 2965

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 2965
Study: 17028466

Group type: EXPERIMENTAL
Intervention: Conservative treatment of patients with HELLP syndrome
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prompt delivery
Number of subjects: 0
Study: 14711132

Group type: EXPERIMENTAL
Intervention: Pharmacological interventions (chemical agents)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Behavioral/psychosocial interventions (manual-guided therapy)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Treatment services
Number of subjects: 0
Study: 10890339

Group type: EXPERIMENTAL
Intervention: Acupuncture + mobilization
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ear acupuncture + mobilization
Number of subjects: 60

Group type: COMPARATOR
Intervention: Mobilization alone (control)
Number of subjects: 60
Study: 8818503

Group type: EXPERIMENTAL
Intervention: Le Nez du Vin smell test
Number of subjects: 132

Group type: COMPARATOR
Intervention: University of Pennsylvania Smell Identification Test (UPSIT)
Number of subjects: 132
Study: 1581404

Group type: EXPERIMENTAL
Intervention: Conventional maintenance therapy
Number of subjects: 448

Group type: EXPERIMENTAL
Intervention: Intensive postconsolidation therapy
Number of subjects: 448

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 448
Study: 3878682

Group type: EXPERIMENTAL
Intervention: Ringer's lactate
Number of subjects: 19

Group type: COMPARATOR
Intervention: Ringer's acetate
Number of subjects: 19
Study: 31314957

Group type: EXPERIMENTAL
Intervention: sLV5FU2 group
Number of subjects: 114

Group type: COMPARATOR
Intervention: gemcitabine group
Number of subjects: 114
Study: 29419653

Group type: EXPERIMENTAL
Intervention: Naldemedine 0.2 mg once daily
Number of subjects: 623
Study: 27457913

Group type: EXPERIMENTAL
Intervention: Traditional Periodization (TP)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Daily Undulating Periodization (DUP)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control (Washout Period)
Number of subjects: 11
Study: 24385033

Group type: EXPERIMENTAL
Intervention: External rotation brace (n = 31)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Internal rotation sling (n = 29)
Number of subjects: 60
Study: 22294668

Group type: EXPERIMENTAL
Intervention: Hartmann's and 5% dextrose at full maintenance rate
Number of subjects: 82

Group type: COMPARATOR
Intervention: 0.45% saline and 5% dextrose at two-thirds maintenance rate
Number of subjects: 82
Study: 19940437

Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 274
Study: 17631074

Group type: COMPARATOR
Intervention: Valsartan 160 mg
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Valsartan 160 mg plus Simvastatin 20 mg
Number of subjects: 404

Group type: EXPERIMENTAL
Intervention: Valsartan 160 mg plus Simvastatin 80 mg
Number of subjects: 404
Study: 16133688

Group type: COMPARATOR
Intervention: ALN 5 mg once daily
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: ALN 35 mg once weekly
Number of subjects: 328
Study: 11845375

Group type: EXPERIMENTAL
Intervention: 2.5 mg droperidol
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 10 mg metoclopramide
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (2 ml NaCl 0.9%)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Quintuple prophylaxis (10 mg metoclopramide, 2.5 mg droperidol, 12.5 mg dolasetron, 62.5 mg dimenhydrinate, 8 mg dexamethasone)
Number of subjects: 120
Study: 11072390

Group type: EXPERIMENTAL
Intervention: Persuasive simulated radio message on the risks of Light cigarettes
Number of subjects: 568
Study: 7669374

Group type: EXPERIMENTAL
Intervention: Intravenous morphine infusion (loading dose of 100 micrograms/kg over 30 min followed by continuous infusion at 10 micrograms/kg per hour)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Intravenous morphine infusion
Number of subjects: 26
Study: 1735983

Group type: EXPERIMENTAL
Intervention: University of Wisconsin solution (UWS)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Conventional preservation using crystalloid cardioplegia and saline storage (CCS)
Number of subjects: 42
Study: 6704504

Group type: EXPERIMENTAL
Intervention: Formulation A
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Formulation B
Number of subjects: 5

Group type: COMPARATOR
Intervention: Formulation A and B
Number of subjects: 5

Group type: COMPARATOR
Intervention: RIA and GC‐MS
Number of subjects: 5
Study: 31068161

Group type: EXPERIMENTAL
Intervention: AIMS interventions (Unit‐based Physician Teams, Unit Nurse‐Physician Co‐leadership, Enhanced Interprofessional Rounds, Unit‐level Performance Reports, Patient Engagement Activities)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 29954454

Group type: EXPERIMENTAL
Intervention: Bifidobacterium adolescentis IVS‐1
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Galactooligosaccharides (GOS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bifidobacterium lactis BB‐12
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GOS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Bifidobacterium adolescentis IVS‐1 + GOS
Number of subjects: 0
Study: 26912209

Group type: EXPERIMENTAL
Intervention: Fluticasone/formoterol 500/20 μg (high dose)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Fluticasone/formoterol 100/10 μg (low dose)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 23344106

Group type: EXPERIMENTAL
Intervention: Dronedarone (400 mg bid)
Number of subjects: 4628

Group type: EXPERIMENTAL
Intervention: Dronedarone
Number of subjects: 4628

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4628
Study: 23059576

Group type: EXPERIMENTAL
Intervention: UT-e (ultrasound etched)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: DB-e (diamond burs etched)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: UT-n/e (ultrasound non-etched)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: DB-n/e (diamond burs non-etched)
Number of subjects: 16
Study: 19960350

Group type: EXPERIMENTAL
Intervention: Usual endurance training combined with heavy strength training (E + S)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Usual endurance training only (E)
Number of subjects: 20
Study: 17401014

Group type: EXPERIMENTAL
Intervention: Sucralfate during pelvic radiotherapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Pelvic radiotherapy without sucralfate (control group not explicitly mentioned)
Number of subjects: 0
Study: 16293780

Group type: EXPERIMENTAL
Intervention: 10-week program of group sessions (1.5 hours per week) offering social support and education
Number of subjects: 116

Group type: COMPARATOR
Intervention: Standard list of community resources and option to participate in group sessions at the end of follow-up
Number of subjects: 116
Study: 11897643

Group type: EXPERIMENTAL
Intervention: Nasal continuous positive airway pressure (CPAP) for 8 weeks
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo tablet for 8 weeks
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Nasal CPAP
Number of subjects: 42
Study: 10193670

Group type: EXPERIMENTAL
Intervention: enalapril 20 mg alone
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: enalapril 20 mg with propranolol 80 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: lisinopril 20 mg alone
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: lisinopril 20 mg with propranolol 80 mg
Number of subjects: 12
Study: 7773825

Group type: EXPERIMENTAL
Intervention: Diagnostic home visit
Number of subjects: 141
Study: 2268940

Group type: EXPERIMENTAL
Intervention: Xiaobu Jianfei Pian (XJP)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Fangfeng Tongsheng San
Number of subjects: 51
Study: 7040142

Group type: EXPERIMENTAL
Intervention: Low fat diet advice
Number of subjects: 0

Group type: COMPARATOR
Intervention: Low carbohydrate diet advice
Number of subjects: 0
Study: 31433259

Group type: EXPERIMENTAL
Intervention: ReSound Assist (app-based communication)
Number of subjects: 30

Group type: COMPARATOR
Intervention: In-person follow-up appointments (control)
Number of subjects: 30
Study: 30056586

Group type: EXPERIMENTAL
Intervention: PBMT 60 J/arm
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: PBMT 90 J/arm
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: PBMT 120 J/arm
Number of subjects: 15
Study: 28756267

Group type: EXPERIMENTAL
Intervention: Celecoxib 100 to 200 mg twice daily
Number of subjects: 24081

Group type: EXPERIMENTAL
Intervention: Naproxen 375 to 500 mg twice daily
Number of subjects: 24081

Group type: EXPERIMENTAL
Intervention: Ibuprofen 600 to 800 mg thrice daily
Number of subjects: 24081
Study: 27544988

Group type: EXPERIMENTAL
Intervention: Novel well-padded new fighting vest (NFV)
Number of subjects: 243

Group type: COMPARATOR
Intervention: Standard unisex special unit fighting vest (SUFV)
Number of subjects: 243
Study: 25115428

Group type: EXPERIMENTAL
Intervention: Pulsed-dye laser
Number of subjects: 147

Group type: EXPERIMENTAL
Intervention: Fractional CO2 laser
Number of subjects: 147
Study: 23114559

Group type: EXPERIMENTAL
Intervention: Intensive 12-week strength-power training, twice a week, supervised by a physiotherapist
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 46
Study: 19460849

Group type: EXPERIMENTAL
Intervention: DDD/R plus ATP pacing
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: DDD/R plus ATP and prevention pacing
Number of subjects: 71

Group type: COMPARATOR
Intervention: DDD/R pacing
Number of subjects: 71
Study: 17259833

Group type: EXPERIMENTAL
Intervention: Single-dose sodium phosphate (45 mL)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Double-dose sodium phosphate (90 mL)
Number of subjects: 100